Promis Neurosciences Stock News

ProMIS Neurosciences (TSX:PMN) told investors it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer's d

The shares of ProMIS Neurosciences Inc. (Nasdaq: PMN) surged 32.33% in its Nasdaq debut. These are some details you should know.

TORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therap

Optimizing vaccine design for Alzheimer's disease Optimizing vaccine design for Alzheimer's disease

ProMIS Neurosciences (ARFXF) initiated a program to develop monoclonal antibodies to treat schizophrenia and other chronic mental illnesses.The company said that biomedical literature…

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antib

TORONTO, Ontario and CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairmans Memorandum commenting on the Companys progress over the past year and outlook for 2022.

ProMIS Neurosciences (OTCMKTS: ARFXF) is one of 42 publicly-traded companies in the Commercial physical research industry, but how does it contrast to its competitors? We will compare ProMIS Neurosciences to related businesses based on the strength of its dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Risk & Volatility ProMIS Neurosciences has a []

ProMIS Neurosciences (OTCMKTS: ARFXF) is one of 42 public companies in the Commercial physical research industry, but how does it compare to its competitors? We will compare ProMIS Neurosciences to similar businesses based on the strength of its dividends, valuation, profitability, institutional ownership, earnings, analyst recommendations and risk. Institutional and Insider Ownership 0.0% of ProMIS []

ProMIS Neurosciences (OTCMKTS: ARFXF) is one of 42 public companies in the Commercial physical research industry, but how does it compare to its peers? We will compare ProMIS Neurosciences to related companies based on the strength of its analyst recommendations, dividends, valuation, risk, profitability, earnings and institutional ownership. Profitability This table compares ProMIS Neurosciences and []

TORONTO and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the Company ), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce shareholders passed the share consolidation resolution at its special general meeting of shareholders (the Special Meeting ) held on December 1, 2021.

ProMIS Neurosciences (OTCMKTS: ARFXF) is one of 42 publicly-traded companies in the Commercial physical research industry, but how does it compare to its peers? We will compare ProMIS Neurosciences to related businesses based on the strength of its earnings, analyst recommendations, dividends, valuation, profitability, risk and institutional ownership. Analyst Ratings This is a breakdown of []

ProMIS Neurosciences (OTCMKTS: ARFXF) is one of 42 publicly-traded companies in the Commercial physical research industry, but how does it weigh in compared to its competitors? We will compare ProMIS Neurosciences to related businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability. Analyst Recommendations This is a []

ProMIS Neurosciences (OTCMKTS: ARFXF) is one of 42 publicly-traded companies in the Commercial physical research industry, but how does it weigh in compared to its rivals? We will compare ProMIS Neurosciences to similar businesses based on the strength of its profitability, risk, institutional ownership, analyst recommendations, valuation, dividends and earnings. Risk & Volatility ProMIS Neurosciences []

ProMIS Neurosciences (OTCMKTS: ARFXF) is one of 42 publicly-traded companies in the Commercial physical research industry, but how does it compare to its competitors? We will compare ProMIS Neurosciences to similar companies based on the strength of its valuation, dividends, institutional ownership, earnings, risk, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of []